[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-nodules\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-nodules":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,48,80,109,134,153,176,211,231,251],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644901","phase-4-pre-emptive-parecoxib-sodium-for-pain-control-during-ct-guided-lung-nodule-localization-100644901",false,"NCT07675473","Pre-Emptive Parecoxib Sodium for Pain Control During CT-Guided Lung Nodule Localization","Application of Pre-Emptive Analgesia With Parecoxib Sodium in CT-Guided Hook Wire Localization of Lung Nodules Before Video-Assisted Thoracoscopic Surgery and Exploration of the Optimal Clinical Dosing Window: A Single-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","PEARL","Inclusion Criteria:\n\n* Voluntarily agreed to participate in the study and signed the informed consent form approved by the Ethics Committee.\n* Male or female adult patients aged 18 years or older.\n* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) scheduled for Video-Assisted Thoracoscopic Surgery (VATS).\n* Requires preoperative CT-guided hook wire localization of lung nodules.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* American Society of Anesthesiologists (ASA) physical status classification of I or II.\n* Fully conscious with no psychiatric or neurological disorders, and capable of fully understanding and correctly using the Visual Analog Scale (VAS) for pain assessment.\n\nExclusion Criteria:\n\n* Known history of hypersensitivity to parecoxib sodium, other COX-2 inhibitors, sulfonamides, aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs).\n* History or presence of active peptic ulcer disease, gastrointestinal bleeding, or gastrointestinal perforation.\n* Severe cardiovascular diseases, including but not limited to unstable angina, history of myocardial infarction within the past 6 months, severe arrhythmias, or poorly controlled hypertension.\n* Coagulation disorders with a bleeding tendency (e.g., hemophilia) or currently receiving full-dose anticoagulation therapy, which the investigator believes may significantly increase the bleeding risk of the hook wire localization.\n* Severe, uncontrolled pulmonary diseases (e.g., severe chronic obstructive pulmonary disease \\[COPD\\], interstitial pneumonia) that the investigator believes pose an unacceptable risk for the procedure.\n* Currently using other analgesic medications that cannot be discontinued during the study period.\n* Any other conditions that, in the investigator's judgment, might interfere with the outcome assessment or increase the risk to the subject.","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Before undergoing minimally invasive lung surgery, patients with small lung nodules often need a procedure called \"CT-guided hook wire localization.\" This involves using a CT scanner to help doctors place a tiny wire in the lung to mark the exact location of the nodule for the surgeon. While very helpful for the surgery, this wire placement can be highly painful for patients.\n\nThe main purpose of this clinical trial is to find out if giving patients a pain-relieving medication called parecoxib sodium before the procedure can effectively reduce their pain. Parecoxib sodium is a standard, non-opioid painkiller given through an IV.\n\nAdditionally, researchers want to discover the best time to give this medication. Because operating room schedules can change, patients will receive the IV medication at different times before their localization procedure (ranging from less than an hour to more than 3 hours beforehand). By looking at these different wait times, researchers hope to identify the \"golden window\"-the exact timing that provides the most pain relief.\n\nDuring the study, participants will be randomly assigned by a computer to one of two groups:\n\nThe Study Group: Will receive the active pain medication (parecoxib sodium).\n\nThe Control Group: Will receive a placebo (a saltwater solution with no active medicine).\n\nTo ensure the results are fair and unbiased, participants have a 2 in 3 chance of receiving the active medication, and neither the patients nor their doctors will know which assignment they received. Immediately after the wire is placed, participants will be asked to rate their pain on a scale of 0 to 10.\n\nBy comparing the pain scores between the two groups and looking at the different medication timings, researchers hope to create better, more comfortable care guidelines for future lung surgery patients.",[27],"Lung Nodules",[29,30,31,32,33,34],"Parecoxib Sodium","Hook Wire","Lung Nodule","CT-Guided Localization","Pre-Emptive Analgesia","Pain Management","RECRUITING","2026-06-25",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":21},"2026-06-01",{"date":43,"type":21},"2028-06-15",{"name":45,"class":46},"Long Jiang","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100643349","ctdna-mutations-and-methylation-status-for-early-detection-of-lung-cancer-in-patients-with-suspicious-lung-nodules-100643349","NCT07615556","ctDNA Mutations and Methylation Status for Early Detection of Lung Cancer in Patients With Suspicious Lung Nodules","Circulating Tumor DNA Mutations and Methylation Status as Biomarkers for Early Detection of Lung Cancer in Patients With Suspicious Lung Nodules","Inclusion Criteria:\n\n1. Age 45 - 80 years;\n2. Suspicious lung nodules (\\> 0.5 - 30mm in longest diameter, non-calcified) found within the past six months, or if PET scan has been done before, the specific uptake value (SUV) should be more than 1\n\nExclusion Criteria:\n\n1. Age \\\u003C 45 or \\> 80;\n2. Lung nodules of \\\u003C 0.5 cm in longest diameter, or with calcification seen in imaging;\n3. Known lung cancer or lung metastasis before, or history of extra-pulmonary cancer;\n4. Active tuberculosis;\n5. Clinical unstable conditions including untreated ischemic heart disease or arrhythmia, uncontrolled airway disease;\n6. Unwillingness to undergo invasive investigation like bronchoscopy;\n7. Unable to provide informed written consent.","45 Years","80 Years",{"count":58,"type":21},200,"2 Years","OBSERVATIONAL","Lung Cancer is common in Asia and is different from lung cancer from Western countries in terms of lung cancer epidemiology and management. Lung cancer can be detected early but most early-stage lung cancer appear as lung nodules with suspicious features on imaging. Workup and surveillance for subjects with suspicious lung nodule is a clinical problem. There is no consensus and clinical practice usually varies with local epidemiology of lung diseases namely the local clinical characteristics especially with lung cancer and pulmonary tuberculosis. The clinical challenge is to address whether pulmonary nodules identified on CT screening carry short- and long-term risk for lung cancer. The main objective of this study is to test the improvement of efficiency of diagnostic evaluation with clinical parameters and ctDNA mutation\u002Fmethylation profiling for artificial intelligence modeling of for early detection of lung cancer in subjects with suspicious lung nodules. The hypothesis is that ctDNA mutation and methylation will enhance early detection of lung cancer in patients with suspicious lung nodules. This is a longitudinal cohort study. A total of 200 subjects (100 from Hong Kong and 100 from Vietnam) with suspicious lung nodules on CT Thorax will be recruited. Blood samples will be collected at recruitment and subsequent 6 months follow up. ctDNA mutations and methylation with SPOTMAS Lung assays would be performed at baseline and at 6 months follow-up. The CT scan where the suspicious lung nodules were identified, will be used as baseline scan for recruitment. Recruited subjects will be arranged with a non-contrast LDCT scans at 6 months follow-up. The primary outcome measure of the study is the detection of ctDNA mutation and methylation in correlation with diagnosis of lung cancer or persistence of suspicious lung nodules. The secondary outcome measures of the study are the Sensitivity and specificity of clinical biomarkers in correctly identifying malignant lung nodule, i.e., lung cancer.",[27,63,64],"Lung Cancer Screening","Suspected Lung Cancer",[66,67,68,69],"ctDNA mutation","Methylation status","Early detection of lung cancer","Suspicious lung nodules","NOT_YET_RECRUITING","2026-06-04",{"date":73,"type":39},"2026-06-08",{"date":75,"type":21},"2026-06",{"date":77,"type":21},"2028-12",{"name":79,"class":46},"The University of Hong Kong",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":106,"locationsCount":108},"100624619","shape-sensing-versus-electromagnetic-robotic-bronchoscopy-for-evaluation-of-pulmonary-lesions-100624619","NCT07411989","Shape-sensing Versus Electromagnetic Robotic Bronchoscopy for Evaluation of PulmoNary LEsions","Shape-sensing Versus Electromagnetic Robotic Bronchoscopy for Evaluation of PulmoNary LEsions: the SERENE Trial","SERENE","Inclusion Criteria:\n\n1. ≥ 18 years of age at time of bronchoscopy\n2. Scheduled for navigational bronchoscopy for the evaluation of pulmonary lesion\n\nExclusion Criteria:\n\n1\\. Inability to provide informed consent",{"count":89,"type":21},346,[91],"NA","This is an investigator-initiated, multicenter, non inferiority, cluster randomized controlled trial. The primary objective is to compare the diagnostic yield of the electromagnetic robotic assisted bronchoscopy with digital tomosynthesis (Galaxy system by Noah Medical) to the shape sensing robotic assisted bronchoscopy with integrated cone beam CT (Ion™ Endoluminal System by Intuitive) in patients undergoing bronchoscopy for peripheral pulmonary lesion (PPL) evaluation.",[94,27],"Peripheral Pulmonary Lesions (PPLs)",[96,97,98,99],"Bronchoscopy","Peripheral Pulmonary Lesions","Robotic assisted bronchoscopy","Lung biopsy","2026-05-26",{"date":102,"type":39},"2026-05-28",{"date":104,"type":21},"2026-12",{"date":77,"type":21},{"name":107,"class":46},"The Cleveland Clinic",2,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":132,"locationsCount":47},"100621300","ai-driven-autonomous-registration-in-robotic-bronchoscopy-100621300","NCT07368829","AI-Driven Autonomous Registration in Robotic Bronchoscopy","Feasibility and Safety of Artificial Intelligence-Driven Autonomous Registration in Robotic Navigational Bronchoscopy","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Radiologically confirmed pulmonary nodules requiring preoperative localization.\n* Scheduled for robotic navigational bronchoscopy using the Bronchoscopy Robot System.\n* Willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Severe cardiopulmonary dysfunction (e.g., FEV1 \\\u003C 30% predicted).\n* Coagulopathy or anticoagulation therapy that cannot be safely interrupted.\n* Pregnancy or lactation.\n* Inability to tolerate bronchoscopy under general anesthesia.",{"count":117,"type":21},20,[91],"This study aims to evaluate the feasibility and safety of an artificial intelligence (AI)-driven autonomous registration technology in robotic navigational bronchoscopy. A total of 20 patients with pulmonary nodules requiring localization will be enrolled. The Langhe Bronchoscopy Robot System equipped with AI-based autonomous registration software will be used. Primary outcomes include the success rate of autonomous registration and the rate of manual intervention during the process. Secondary outcomes encompass registration time, complication rates, and nodule localization success.",[27,96,121],"Localization Efficiency",[123,124,125],"Artificial Intelligence","Robotic Bronchoscopy","Pulmonary Nodule","2026-04-09",{"date":128,"type":39},"2026-04-13",{"date":130,"type":39},"2026-03-01",{"date":38,"type":21},{"name":133,"class":46},"Ruijin Hospital",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":149,"leadSponsor":151,"locationsCount":47},"100627423","clinical-study-of-trap-fapi3-pet-imaging-in-the-diagnosis-of-pulmonary-nodules-100627423","NCT07448441","Clinical Study of Trap-(FAPI)3 PET Imaging in the Diagnosis of Pulmonary Nodules","Inclusion Criteria:\n\n* 1\\) Patients aged over 18 years with no gender restriction;\n* 2\\) Patients with radiographic findings of pulmonary nodules;\n* 3\\) Patients eligible for Trap-(FAPI)3 PET examination;\n* 4\\) Written informed consent signed by the subject or their legal guardian.\n\nExclusion Criteria:\n\n* 1\\) Patients who have received antitumor therapy prior to PET\u002FCT scanning;\n* 2\\) Patients with severe diseases that cannot tolerate PET\u002FCT scanning;\n* 3\\) Alternative subjects with contraindications to PET\u002FCT scanning;\n* 4\\) Radiation exposure exceeding 50 mSv dose in the past year;\n* 5\\) Alternative subjects who underwent major surgery within the past 3 months; those who received experimental drugs or devices (with unclear efficacy or safety) within the past 1 month;\n* 6\\) Alternative subjects with any clinical conditions that the principal investigator of this study considers may cause or pose potential hazards from the investigational product.","65 Years",{"count":142,"type":21},50,"The excellent tumor-targeting efficacy of FAP has been confirmed by multiple clinical studies. The results unequivocally establish FAPI as a tumor-targeting ligand with significant potential, demonstrating important application prospects in translational oncology. However, its therapeutic effects remain under investigation. An ideal radiopharmaceutical for cancer treatment should possess outstanding targeting specificity and relatively prolonged tumor retention time. Previous studies have shown that radiolabeled FAPI variants (FAPI-04 and FAPI-46) rapidly and satisfactorily accumulate in tumors, while exhibiting low physiological uptake in normal tissues. However, prior FAP-related tracers demonstrated relatively short retention times in small pulmonary lesions. Our aim is to design a FAPI trimer, Trap-(FAPI)3, to optimize pharmacokinetics and evaluate whether this novel drug offers superior advantages over its monomer analogs in the imaging diagnosis and staging of pulmonary tumors.",[27],"2026-03-02",{"date":147,"type":39},"2026-03-04",{"date":130,"type":21},{"date":150,"type":21},"2027-12-31",{"name":152,"class":46},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":4},"100627046","the-effect-of-acupuncture-on-pulmonary-function-recovery-following-lung-resection-100627046","NCT07443540","The Effect of Acupuncture on Pulmonary Function Recovery Following Lung Resection","The Effect of Acupuncture on Pulmonary Function Recovery Following Lung Resection: A Clinical Trial","Inclusion Criteria:\n\n\\- Patients aged between 18 and 65 years.\n\nDiagnosed with a single pulmonary lesion (e.g., solitary pulmonary nodule or adenocarcinoma in situ).\n\nScheduled to undergo elective wedge resection for the lung lesion.\n\nExclusion Criteria:\n\n* History of prior lung resection.\n\nMedical history of asthma or pulmonary tuberculosis.\n\nHistory of pneumothorax prior to the current surgery.\n\nExpectation to receive rehabilitation therapies other than the standard protocol-defined incentive spirometry during the study period.\n\nPresence of other major systemic diseases (e.g., severe cardiovascular, renal, or hepatic impairment) that, in the investigator's opinion, render the patient unsuitable for trial participation.",{"count":161,"type":21},56,[91],"Background and Purpose:\n\nLung resection surgery is the standard treatment for early-stage lung adenocarcinoma, but it often leads to reduced lung volume and postoperative pain, which can hinder pulmonary recovery. While standard rehabilitation includes breathing exercises (incentive spirometry) and pain management, additional strategies are needed to enhance recovery. Acupuncture has shown benefits in managing respiratory diseases like COPD and reducing surgical pain, but its specific effectiveness in rehabilitation after lung resection has not yet been established. This study aims to evaluate whether adding acupuncture to standard postoperative care can further improve lung function and recovery.\n\nStudy Design and Methods:\n\nThis is a randomized controlled clinical trial. Participants who have undergone lung resection will be assigned to one of two groups:\n\nControl Group: Receives standard rehabilitation (lung volume training with incentive spirometry).\n\nIntervention Group: Receives standard rehabilitation plus acupuncture therapy.\n\nEvaluation:\n\nOne week after surgery, researchers will perform pulmonary function tests on all participants. The study will compare the two groups primarily based on improvements in lung function. Secondary outcomes, including pain levels and quality of life, will also be assessed to determine the overall benefit and safety of integrating acupuncture into postoperative recovery.",[27],[166,167],"Lung nodules","acupuncture","2026-02-25",{"date":145,"type":39},{"date":171,"type":21},"2026-04-01",{"date":173,"type":21},"2027-01-30",{"name":175,"class":46},"Chung Shan Medical University",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":187,"studyType":60,"phases":4,"briefSummary":188,"conditions":189,"keywords":193,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":47},"100597373","shape-sensing-robotic-assisted-bronchoscopy-for-diagnosis-of-peripheral-pulmonary-nodules-in-korea-100597373","NCT07057648","Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea","Shape-sensing Robotic-assisted Bronchoscopy (ssRAB) for Diagnosis of Peripheral Pulmonary Nodules: A Prospective Cohort Study in Korea (the ULSAN-ION Study)","ULSAN-ION","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Solid or part-solid peripheral pulmonary nodules confirmed on chest computed tomography (CT)\n* Patients requiring histological diagnosis as determined by the treating physician\n* Patients eligible for bronchoscopy procedure\n* Ability to provide written informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 or equivalent functional status allowing procedure under sedation or general anesthesia\n\nExclusion Criteria:\n\n* Pure ground glass opacity nodules\n* Bleeding tendency defined as platelet count less than 50,000\u002FμL or International Normalized Ratio (INR) greater than 1.5\n* Severe cardiopulmonary dysfunction precluding deep sedation or general anesthesia\n* Pregnant or breastfeeding women\n* Life expectancy less than 6 months as assessed by the treating physician\n* Inability or unwillingness to provide informed consent\n* Absolute contraindication to bronchoscopy including:\n\n  * Severe hypoxemia (oxygen saturation \\\u003C90% on room air)\n  * Severe pulmonary hypertension\n  * Recent myocardial infarction (within 6 weeks)\n  * Unstable angina\n  * Malignant arrhythmias\n* Participation in another interventional clinical trial that may interfere with study procedures or outcomes","19 Years",{"count":186,"type":21},100,"6 Months","What is this study about? This study tests a new robotic technology to take tissue samples from lung nodules (small spots in the lungs). Some lung nodules are cancer, but doctors need a tissue sample to know for sure.\n\nWhat is the problem? Current methods to get tissue from lung nodules only work about 7 out of 10 times. When they don't work, doctors may need riskier procedures.\n\nWhat is the new technology? The new technology is called robotic bronchoscopy (ssRAB). It uses a robot with special sensors to guide a thin tube more accurately to lung nodules than current methods.\n\nWho can join? Adults aged 19 or older who have lung nodules that need tissue sampling and are healthy enough for the procedure.\n\nWhat happens? Participants will have the robotic procedure while asleep under anesthesia. The robot guides a thin tube to the lung nodule to take a small tissue sample. Participants are watched for problems and followed for 6 months.\n\nWhat are the risks and benefits? The new technology may be more accurate and safer than current methods. The main risks are small chance of lung collapse or bleeding, similar to regular procedures.\n\nWhy is this important? This study will show if the new robotic technology works well and is safe in Korea. If successful, it could help diagnose lung cancer earlier and more accurately.\n\nThis study will include 100 people at Ulsan University Hospital in Korea.",[27,190,191,192,96],"Peripheral Lung Lesions","Pulmonary Nodules","Lung Cancers",[194,195,196,197,198,27,199,99,200,201],"Shape-sensing robotic-assisted bronchoscopy","ssRAB","Robotic bronchoscopy","Peripheral lung nodules","Diagnostic yield","Navigation bronchoscopy","Korea","Prospective cohort","2026-02-10",{"date":204,"type":39},"2026-02-13",{"date":206,"type":39},"2025-07-09",{"date":208,"type":21},"2027-05-31",{"name":210,"class":46},"Ulsan University Hospital",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":217,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":47},"100623835","specimens-for-lung-cancer-panel-design-100623835","NCT07401797","Specimens for Lung Cancer Panel Design","6.1 Criteria for the no prior cancer suspicious nodule arm\n\nInclusion:\n\n1. The patient has at least one indeterminant nodule with a diameter greater than or equal to 5mm and a Mayo SPN risk greater than 5%, identified by radiology, that has not been biopsied or undergone surgery.\n2. The patient and the treating physician intend to follow up on the nodule with a biopsy procedure, PET scan, or active surveillance, with the procedure or next surveillance planned within the next 7 months.\n3. Ability to understand the study and sign an informed consent form\n4. Relevant clinical data accessible\n5. Ability and willingness to safely donate 40 mL of blood\n6. Ability of the site to collect and process blood per protocol Exclusion\n\n1\\. The patient has one or more nodules with a Mayo SPN risk over 50% or a diameter of 30mm or greater.\n\n2\\. The patient has received surgical prep, including antibiotics, anesthesia, etc. Fasting is not exclusionary.\n\n3\\. Previous cancer diagnosis of any origin. 4. Is currently pregnant 5. Is currently a prisoner or becomes a prisoner at any point during the study 6. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf 6.2 Criteria for the previous cancer suspicious nodule arm\n\nInclusion:\n\n1\\. The patient has at least one indeterminant nodule with a diameter greater than or equal to 5mm and a Mayo SPN risk greater than 5%, identified by radiology, that has not been biopsied or undergone surgery.\n\n2\\. The patient and the treating physician intend to follow up on the nodule with a biopsy procedure, PET scan, or active surveillance, with the procedure or next surveillance planned within the next 7 months.\n\n3\\. The patient has been in remission for a previous cancer not of lung origin for more than 5 years.\n\n4\\. Ability to understand the study and sign an informed consent form 5. Relevant clinical data accessible 6. Ability and willingness to safely donate 40 mL of blood 7. Ability of the site to collect and process blood per protocol Exclusion\n\n1. The patient has one or more nodules with a Mayo SPN risk over 50% or a diameter of 30mm or greater.\n2. The patient has received surgical prep, including antibiotics, anesthesia, etc. Fasting is not exclusionary.\n3. Previous cancer diagnosis in the lung (either of lung origin or metastasis to the lung).\n4. The treating physician believes the lung nodule is a recurrence of a previously diagnosed cancer.\n5. Is currently pregnant\n6. Is currently a prisoner or becomes a prisoner at any point during the study\n7. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf\n\n6.3 Criteria for the healthy volunteer arm\n\nInclusion:\n\n1. Ability to understand the study and sign an informed consent form\n2. Relevant clinical data accessible\n3. Ability and willingness to safely donate up to 40 mL of blood\n4. The ability of the site to collect and process blood per protocol Exclusion\n\n1\\. Is currently pregnant 2. Is currently a prisoner or becomes a prisoner at any point during the study 3. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf",true,{"count":219,"type":21},2000,"This is an observational study designed to determine the optimal combination of biomarkers and clinical data for the early detection, confirmation, and better treatment of lung cancer including minimizing recurrence.",[27],"2026-02-03",{"date":202,"type":39},{"date":225,"type":39},"2024-08-07",{"date":227,"type":21},"2029-12-31",{"name":229,"class":230},"Maverix Medical","INDUSTRY",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":47},"100579219","bronchoscopic-navigation-robot-guided-dye-marking-assisted-thoracoscopic-pulmonary-nodule-resection-100579219","NCT06821451","Bronchoscopic Navigation Robot-guided Dye Marking-assisted Thoracoscopic Pulmonary Nodule Resection","A Prospective, Single-center, Non-inferiority Clinical Trial Study Evaluating the Effectiveness and Safety of Bronchoscopic Navigation Robot (bronchial Navigation Positioning Device) Guided Dye Marking-assisted Thoracoscopic Pulmonary Nodule Resection","Inclusion Criteria:\n\n* Aged 18-80 years, regardless of gender;\n* Peripheral pulmonary nodules, planned for single lesion non-anatomical sublobar resection via thoracoscopic assistance after preoperative discussion;\n* Preoperative assessment indicates that the pulmonary nodules cannot be localized through visual inspection or palpation;\n* Patients are able to understand the purpose of the trial, have good compliance with examinations and follow-ups, and voluntarily participate in the clinical trial by signing an informed consent form.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will be excluded from this study:\n\n\\- Surgical contraindications that do not meet surgical tolerance standards: fulfilling one major criterion and\u002For two or more minor criteria.\n\nMajor criterion: Forced expiratory volume in 1 second (FEV1) or carbon monoxide diffusion capacity (DLCO) ≤ 50%.\n\nMinor criterion: (1) FEV1 or DLCO 51%-60%; (2) Age ≥ 75 years; (3) Pulmonary hypertension \\> 40 mmHg (1 mmHg = 0.133 kPa); (4) Left ventricular ejection fraction (LVEF) ≤ 40%; (5) Arterial blood partial pressure of oxygen (PaO2) \\\u003C 55 mmHg or arterial blood oxygen saturation (SpO2) ≤ 88% with arterial blood partial pressure of carbon dioxide (PaCO2) \\> 45 mmHg.\n\n* Contraindications for bronchoscopy, including: active massive hemoptysis; recent myocardial infarction or unstable angina; severe hypertension and arrhythmias; uncorrectable bleeding tendencies (such as severe coagulopathy, uremia, and severe pulmonary hypertension, etc.); severe superior vena cava syndrome; suspected aortic aneurysm; multiple pulmonary bullae; extremely poor overall condition;\n* Female patients who are breastfeeding, pregnant, or trying to conceive;\n* Patients with electromagnetic active implantable devices;\n* Participants allergic to indocyanine green or anesthetics; or with a history of multiple severe allergies or hereditary allergies;\n* Participation in drug clinical trials in the past 3 months, or currently participating, or participation in other medical device clinical trials within the past 30 days;\n* Other conditions deemed unsuitable for participation in this clinical trial by the investigator.",{"count":239,"type":21},80,[91],"With the widespread use of low-dose spiral CT screening for the lungs, an increasing number of small nodules are being detected, and surgical resection is the preferred method for clinical intervention of pulmonary nodules. Staining localization can assist surgeons in accurately locating pulmonary nodules during surgery, achieving complete resection of the nodules while minimizing the resection area, thereby optimizing surgical outcomes.\n\nThe study will include individuals with pulmonary nodules detected by CT scans who require color localization assistance for thoracoscopic pulmonary nodule resection, randomly divided into two groups: one group will receive bronchoscopic navigation-assisted staining localization, while the other group will receive staining localization guided by an electromagnetic navigation system. The primary outcome is to evaluate the success rate of staining localization between the two groups.\n\nThis study aims to assess, through a prospective, single-center, randomized controlled clinical trial, whether the success rate of staining localization guided by bronchoscopic navigation robots (experimental group) is not lower than that of staining localization guided by the electromagnetic navigation system (control group), while potentially offering advantages such as a shorter learning curve, ease of operation, and reduced surgical time. This will provide a new efficient and safe method for the localization of pulmonary nodules clinically, greatly supporting accurate treatment of pulmonary nodules.",[27],"2025-02-09",{"date":245,"type":39},"2025-02-12",{"date":247,"type":21},"2025-02-10",{"date":249,"type":21},"2026-03-31",{"name":133,"class":46},{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":47},"100576744","the-impact-of-thoracic-paravertebral-nerve-block-at-different-positions-on-pain-relief-in-patients-undergoing-single-port-thoracoscopic-partial-lung-resection-100576744","NCT06789276","The Impact of Thoracic Paravertebral Nerve Block At Different Positions on Pain Relief in Patients Undergoing Single-Port Thoracoscopic Partial Lung Resection","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 70 years old\n\n  * BMI ≥ 18 and ≤ 28\n\n    * American Society of Anesthesiologists (ASA) physical status classification I-II ⑷ Patients scheduled for elective thoracoscopic lung resection (including lobectomy, segmentectomy, and wedge resection) ⑸ Patients who agree to participate in this study and sign the informed consent form\n\nExclusion Criteria:\n\n* Patients who refuse to undergo nerve block\n\n  * Patients with severe cardiac, pulmonary, hepatic, or renal insufficiency requiring postoperative admission to the ICU for continued treatment (EF \\\u003C 40%, FEV1\u002FFVC \\\u003C 40%)\n\n    * Abnormal coagulation function ⑷ History of allergy to anesthetic drugs\n\n      * History of chronic alcohol use, chronic pain, or long-term use of psychotropic medications ⑹ Scars, infections, or tumors at the puncture site ⑺ History or family history of malignant hyperthermia ⑻ Refusal to participate in this study or inability to cooperate with follow-up or poor compliance\n\nTermination criteria:\n\n* Failure to comply with the predetermined study protocol ⑵ Occurrence of local anesthetic adverse reactions, puncture needle entering the pleural cavity, or other complications during puncture\n\n  * Changes in the patient's condition ⑷ The patient's unwillingness to continue participating in the study","70 Years",{"count":58,"type":21},[91],"Thoracic surgery is widely recognized as one of the most painful surgical procedures. Compared to open thoracotomy, video-assisted thoracoscopic surgery (VATS) offers similar therapeutic outcomes with less invasiveness, significantly reducing postoperative pain and promoting recovery. Despite the use of video-assisted thoracoscopic surgery (VATS), a significant proportion of patients still experience considerable discomfort. Specifically, 78% of patients report moderate to severe pain, with 27% experiencing moderate pain, 34% severe pain, and 17% very severe pain.\n\nMultiple studies have shown that the use of regional anesthesia, such as thoracic paravertebral nerve block (TPVB), in these surgeries can block the transmission of nociceptive signals via the intercostal nerves, producing good analgesic effects. This can reduce the consumption of postoperative opioids, decrease inflammatory responses, and improve patient survival rates after surgery.\n\nBy comparing the differences in hemodynamic parameters, inflammatory stress indicators, and intraoperative and postoperative analgesic effects of thoracic paravertebral nerve block in different preoperative positions for patients undergoing thoracoscopic surgery, we aim to identify the optimal nerve block position, thereby promoting patient recovery.",[27,262],"Lung Cancer","2025-01-22",{"date":265,"type":39},"2025-01-23",{"date":267,"type":21},"2025-01-18",{"date":269,"type":21},"2025-12-31",{"name":271,"class":46},"Second Affiliated Hospital of Soochow University"]